Botulinum toxin type A influences stump pain after limb amputations [1]

Journal of Pain and Symptom Management

Volumn 26, Issue 6, 2003, Pages 1069-1070

  Kern, Uwe ^a   Martin, Conchita ^a   Scheicher, Sigrun ^a   Müller, Hermann ^a  

^a Dept Anesth   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ABOVE KNEE AMPUTATION; ADULT; AGED; AMPUTATION STUMP; ANALGESIC ACTIVITY; BELOW KNEE AMPUTATION; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERHIDROSIS; LEG AMPUTATION; LETTER; LIMB AMPUTATION; LIMB PAIN; MALE; MUSCLE SPASM; PAIN ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PILOT STUDY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 0345707684     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2003.09.003     Document Type: Letter

References (13)

1. Kern U., Martin C., Scheicher S., Müller H. Treatment of phantom pain with botulinum-toxin A. A pilot study. Schmerz. 17:(2):2003;117-124.
2. Kooijman C.M., Dijkstra P.U., Geertzen J.H., Elzinga A., van der Schans C.P. Phantom pain and phantom sensations in upper limb amputees: an epidemiological study. Pain. 87:(1):2000;33-41.
3. Ehde D.M., Czerniecki J.M., Smith D.G., et al. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. Arch Phys Med Rehabil. 81:(8):2000;1039-1044.
4. Hill A. Phantom limb pain: a review of the literature on attributes and potential mechanisms. J Pain Symptom Manage. 17:(2):1999;125-142.
5. Baron R., Maier C. Phantom limb pain: are cutaneous nociceptors and spinothalamic neurons involved in the signaling and maintenance of spontaneous and touch-evoked pain? A case report. Pain. 60:(2):1995;223-228.
6. Huse E., Larbig W., Birbaumer N., Flor H. Kortikale Reorganisation und Schmerz Empirische Befunde und therapeutische Implikationen am Beispiel des Phantomschmerzes. Schmerz. 15:(2):2001;131-137.
7. Flor H. Phantom-limb pain: Characteristics, causes, and treatment. The Lancet Neurology. 1:(3):2002;182-189.
8. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 33:(3):1981;155-188.
9. Filippi G.M., Errico P., Santarelli R., et al. A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 113:(3):1993;400-404.
10. Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 59:(11):2000;1403-1406.
11. Humm A.M., Pabst C., Lauterburg T., Burgunder J.M. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol. 161:(1):2000;361-372.
12. Kanovsky P., Streitova H., Dufek J., et al. Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A. Mov Disord. 13:(1):1998;108-117.
13. Ceballos-Baumann A.O., Sheean G., Passingham R.E., Marsden C.D., Brooks D.J. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. Brain. 120:(Pt 4):1997;571-582.